系统性红斑狼疮中针对B细胞：并非只是似曾相识。
Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again.
作者信息
Eisenberg Robert
机构信息
Division of Rheumatology, Department of Medicine, University of Pennsylvania, School of Medicine, 756 BRBII/III, 421 Curie Boulevard, Philadelphia, PA 19104-6160, USA.
出版信息
Arthritis Res Ther. 2006;8(3):108. doi: 10.1186/ar1967. Epub 2006 May 15.
Abstract
Epratuzumab (anti-CD22) is a humanized monoclonal antibody that recognizes a pan-B-cell marker. It potentially downregulates B cell activity through negative signaling, as well as depleting B cells moderately. The uncontrolled series discussed by Dörner and colleagues in this issue of Arthritis Research & Therapy suggests that epratuzumab may be safe and efficacious for systemic lupus erythematosus. A randomized controlled trial is currently active to test this possibility.
摘要
依帕珠单抗（抗CD22）是一种识别全B细胞标志物的人源化单克隆抗体。它可能通过负信号传导下调B细胞活性，并适度消耗B细胞。多纳及其同事在本期《关节炎研究与治疗》中讨论的非对照系列研究表明，依帕珠单抗可能对系统性红斑狼疮安全有效。目前正在进行一项随机对照试验以验证这一可能性。
相似文献
1
Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again.系统性红斑狼疮中针对B细胞：并非只是似曾相识。
Arthritis Res Ther. 2006;8(3):108. doi: 10.1186/ar1967. Epub 2006 May 15.
2
Epratuzumab for systemic lupus erythematosus.依帕珠单抗治疗系统性红斑狼疮。
Lupus. 2013 Apr;22(4):400-5. doi: 10.1177/0961203312469692.
3
The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus.依帕珠单抗与 CD22 结合对 B 细胞功能的作用机制：对系统性红斑狼疮治疗的影响。
Autoimmun Rev. 2015 Dec;14(12):1079-86. doi: 10.1016/j.autrev.2015.07.013. Epub 2015 Jul 23.
4
Treatment of systemic lupus erythematosus with epratuzumab.依帕珠单抗治疗系统性红斑狼疮。
Br J Clin Pharmacol. 2011 Feb;71(2):175-82. doi: 10.1111/j.1365-2125.2010.03767.x.
5
B cell therapy with the anti-CD22 monoclonal antibody epratuzumab: comment on the editorial by St. Clair and Tedder.使用抗CD22单克隆抗体依帕珠单抗进行B细胞治疗：对圣克莱尔和特德编辑文章的评论
Arthritis Rheum. 2006 Jul;54(7):2344; author reply 2344-5. doi: 10.1002/art.21937.
6
Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases.依帕珠单抗（人源化抗CD22抗体）在自身免疫性疾病中的应用。
Expert Opin Biol Ther. 2006 Sep;6(9):943-9. doi: 10.1517/14712598.6.9.943.
7
Epratuzumab for the treatment of systemic lupus erythematosus.依帕珠单抗治疗系统性红斑狼疮。
Expert Rev Clin Immunol. 2018 Apr;14(4):245-258. doi: 10.1080/1744666X.2018.1450141. Epub 2018 Mar 20.
8
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus.依帕珠单抗（人源化抗CD22抗体）用于系统性红斑狼疮免疫治疗的初步临床试验。
Arthritis Res Ther. 2006;8(3):R74. doi: 10.1186/ar1942. Epub 2006 Apr 21.
9
Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials.依帕珠单抗，一种抗 CD22 单克隆 IgG 抗体，在伴有干燥综合征的系统性红斑狼疮患者中的疗效：来自 EMBODY 试验的事后分析。
Arthritis Rheumatol. 2018 May;70(5):763-773. doi: 10.1002/art.40425. Epub 2018 Apr 12.
10
Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus.评估依帕珠单抗作为系统性红斑狼疮的生物疗法。
Immunotherapy. 2014;6(11):1165-75. doi: 10.2217/imt.14.80.
引用本文的文献
1
Selective Histone Deacetylase 6 Inhibition Normalizes B Cell Activation and Germinal Center Formation in a Model of Systemic Lupus Erythematosus.选择性组蛋白去乙酰化酶 6 抑制可使系统性红斑狼疮模型中的 B 细胞活化和生发中心形成正常化。
Front Immunol. 2019 Oct 25;10:2512. doi: 10.3389/fimmu.2019.02512. eCollection 2019.
2
Treatment of systemic lupus erythematosus with epratuzumab.依帕珠单抗治疗系统性红斑狼疮。
Br J Clin Pharmacol. 2011 Feb;71(2):175-82. doi: 10.1111/j.1365-2125.2010.03767.x.
3
B-cell-directed therapies for autoimmune disease.用于自身免疫性疾病的B细胞定向疗法。
Nat Rev Rheumatol. 2009 Aug;5(8):433-41. doi: 10.1038/nrrheum.2009.141. Epub 2009 Jul 7.
4
[Novel B-cell directed strategies for the treatment of rheumatic diseases].[治疗风湿性疾病的新型B细胞导向策略]
Z Rheumatol. 2009 Jul;68(5):380-9. doi: 10.1007/s00393-009-0438-2.
5
Why can't we find a new treatment for SLE?为什么我们找不到系统性红斑狼疮的新治疗方法？
J Autoimmun. 2009 May-Jun;32(3-4):223-30. doi: 10.1016/j.jaut.2009.02.006. Epub 2009 Mar 28.
本文引用的文献
1
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus.依帕珠单抗（人源化抗CD22抗体）用于系统性红斑狼疮免疫治疗的初步临床试验。
Arthritis Res Ther. 2006;8(3):R74. doi: 10.1186/ar1942. Epub 2006 Apr 21.
2
CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction.CD22：一种调节B淋巴细胞存活和信号转导的多功能受体。
Adv Immunol. 2005;88:1-50. doi: 10.1016/S0065-2776(05)88001-0.
3
The therapeutic potential of anti-CD20 "what do B-cells do?".抗CD20的治疗潜力“B细胞有什么作用？”
Clin Immunol. 2005 Dec;117(3):207-13. doi: 10.1016/j.clim.2005.08.006. Epub 2005 Sep 19.
4
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.复发或难治性非霍奇金淋巴瘤中依帕珠单抗和利妥昔单抗联合抗体治疗
J Clin Oncol. 2005 Aug 1;23(22):5044-51. doi: 10.1200/JCO.2005.13.821. Epub 2005 Jun 13.
5
B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.B细胞清除作为系统性红斑狼疮的一种新疗法：利妥昔单抗的I/II期剂量递增试验
Arthritis Rheum. 2004 Aug;50(8):2580-9. doi: 10.1002/art.20430.
6
Final results of a phase I radioimmunotherapy trial using (186)Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma.一项使用（186）Re-依帕珠单抗治疗非霍奇金淋巴瘤患者的I期放射免疫治疗试验的最终结果。
Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3995S-4002S.
7
Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.依帕珠单抗，一种靶向CD22的人源化单克隆抗体：体外特性表征
Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3982S-90S.
8
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.依帕珠单抗（人源化抗CD22抗体）用于惰性非霍奇金淋巴瘤的I/II期试验。
J Clin Oncol. 2003 Aug 15;21(16):3051-9. doi: 10.1200/JCO.2003.01.082. Epub 2003 Jul 1.
9
Dysregulated expression of the Cd22 gene as a result of a short interspersed nucleotide element insertion in Cd22a lupus-prone mice.由于短散在核苷酸元件插入Cd22a狼疮易感小鼠中导致Cd22基因表达失调。
J Immunol. 2000 Sep 15;165(6):2987-96. doi: 10.4049/jimmunol.165.6.2987.
10
Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies.CD22是一种B细胞特异性抑制性受体，其缺陷足以使机体易患高亲和力自身抗体。
J Exp Med. 1999 Apr 19;189(8):1307-13. doi: 10.1084/jem.189.8.1307.
Zotero 插件